[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"decompensated-chronic-heart-failure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:decompensated-chronic-heart-failure":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,39,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100645309","assessment-of-residual-congestion-in-acute-decompensated-heart-failure-100645309",false,"NCT07682298","Assessment of Residual Congestion in Acute Decompensated Heart Failure","VExUS-AHF","Inclusion Criteria:\n\n1. Adults (≥18 years) admitted with ADHF.\n2. Clinical evidence of congestion during admission, indicated by ≥1 of the following: pitting peripheral edema, ascites, elevated jugular venous pressure, or radiologic\u002Fultrasound evidence of pulmonary congestion.\n3. Treatment with ≥40 mg i.v. furosemide or equivalent dose loop diuretic during admission.\n\nExclusion Criteria:\n\n1. Pregnancy\n2. Moribund\n3. Solitary kidney\n4. Inability to provide written consent","ALL","18 Years",{"count":19,"type":20},580,"ESTIMATED","90 Days","OBSERVATIONAL","DESIGN:\n\nA prospective, multicenter, observational cohort study including 580 patients admitted for acute decompensated heart failure (ADHF).\n\nUltrasound assessment of congestion (VExUS and LUS) will be performed serially during admission: within 48 hours of admission, at the time diuretic therapy is switched from intravenous to oral, and on the day of discharge. The discharge assessment will serve as the primary predictor.\n\nTreating physicians will be blinded to all ultrasound findings. Patients will be followed for 90 days by telephone follow-up and chart review for the primary endpoint, with extended chart review at one year for selected secondary endpoints.\n\nAIMS:\n\nTo determine whether combined ultrasound assessment of venous (VExUS) and pulmonary congestion (LUS) at discharge predicts heart failure readmission and all-cause mortality in patients hospitalized with ADHF.\n\nHYPOTHESIS:\n\nAbnormal VExUS and\u002For LUS findings at discharge are associated with a higher risk of heart failure readmission and all-cause mortality after 90 days.",[25,26],"Acute Heart Failure (AHF)","Decompensated Chronic Heart Failure","RECRUITING","2026-07-02",{"date":30,"type":31},"2026-07-07","ACTUAL",{"date":33,"type":31},"2026-02-15",{"date":35,"type":20},"2028-11-01",{"name":37,"class":38},"Aarhus University Hospital","OTHER",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":47,"phases":48,"briefSummary":50,"conditions":51,"keywords":56,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100640061","phase-4-pre-discharge-influenza-vaccination-in-patients-hospitalized-for-acute-cardiac-conditions-100640061","NCT07617376","Pre-discharge Influenza Vaccination in Patients Hospitalized for Acute Cardiac Conditions","Inclusion Criteria:\n\n* Acute cardiac hospitalization,\n* Planned discharge home within the next 48 hours following completion of in-hospital treatment,\n* No prior influenza vaccination for the current influenza season.\n\nExclusion Criteria:\n\n* History of a severe adverse reaction to influenza vaccination,\n* Allergy to any component of the vaccine to be administered,\n* Discharge to another hospital for continuation of treatment or discharge to a long-term care facility,\n* Antibiotic therapy to be continued after discharge.",{"count":46,"type":20},400,"INTERVENTIONAL",[49],"PHASE4","Patients hospitalized for acute cardiac conditions-including acute myocardial infarction, acute heart failure, pulmonary embolism, arrhythmias, and hypertensive emergencies-represent a heterogeneous population at very high risk of recurrent cardiovascular events. Influenza infection may act as a trigger for adverse cardiovascular events. Given the persistently low influenza vaccination uptake despite evidence-based benefits observed in vulnerable populations, including patients with cardiac conditions, new strategies to improve vaccination coverage are being explored. Recently, increasing attention has been directed toward an approach already used in fields such as neonatology, where vaccinations are administered prior to hospital discharge.\n\nIn this investigator-initiated, single-center, randomized, open-label interventional study, we will evaluate whether influenza vaccination administered within 24 hours before hospital discharge in patients hospitalized for acute cardiac conditions is safe and effective in reducing subsequent infections, cardiovascular events, and mortality during the 6 months following hospitalization.",[52,26,25,53,54,55],"Myocardial Infarction","Pulmonary Embolism Acute","Hypertension Emergency","Arrhythmias",[57,58,59],"influenza vaccination","acute cardiac emergencies","pre-discharg vaccination","2026-05-20",{"date":62,"type":31},"2026-06-01",{"date":64,"type":31},"2025-11-12",{"date":66,"type":20},"2027-07-01",{"name":68,"class":38},"Wroclaw Medical University",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":79,"studyType":22,"phases":4,"briefSummary":80,"conditions":81,"keywords":82,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":90,"leadSponsor":92,"locationsCount":95},"100619910","observational-study-designed-to-detect-decompensation-of-congestive-heart-failure-dchf-using-a-non-invasive-wearable-device-100619910","NCT07350759","Observational Study Designed to Detect Decompensation of Congestive Heart Failure (dCHF) Using a Non-Invasive Wearable Device","An Observational Study to Develop an Algorithm to Predict Decompensation of Congestive Heart Failure (dCHF) Using a Non-Invasive Wearable Device.","Inclusion Criteria:\n\n* • Age ≥ 18 years\n\n  * Current use of a hemodynamic sensoring device\n  * At least 4 consecutive weeks of stabilized \"goal\" pulmonary artery pressures\n  * Access to a personal smartphone with Wi-Fi or cellular connectivity\n\nExclusion Criteria:\n\n* • Inability to provide informed consent\n\n  * Inability to read or understand English\n  * Likely non-adherence to wearable device use\n  * Prisoners\n  * Pregnant females",{"count":78,"type":20},60,"1 Year","This is a prospective, observational pilot study designed to develop a mathematical algorithm capable of predicting decompensation of congestive heart failure (dCHF) using physiologic data collected from a non-invasive wearable device. Participants with a remote hemodynamic pulmonary artery pressure monitor will wear a wearable device continuously for up to 12 months. Wearable data will be analyzed in relation to the hemodynamic monitor defined sentinel events of heart failure decompensation to identify predictive signal patterns. Optional biospecimen (DNA, blood, urine) and voice sample collection will support future biomarker discovery.",[26],[83,84,85],"congestive heart failure","wearable monitor","predictive algrothim","2026-03-09",{"date":88,"type":31},"2026-03-11",{"date":86,"type":31},{"date":91,"type":20},"2026-12-31",{"name":93,"class":94},"CHFDX,Inc.","INDUSTRY",2]